

## **Homocysteinaemia in Heart Failure Patients in North Eastern Nigeria**

**Y. A. Ayoola<sup>1,2\*</sup>, H. I. Okolie<sup>2</sup>, O. M. Akinlade<sup>3</sup>, O. G. Oluwatoyin<sup>2</sup>,  
M. W. Ali<sup>2</sup> and S. A. Biliaminu<sup>4</sup>**

<sup>1</sup>Department of Medicine, Gombe State University, Gombe, Nigeria.

<sup>2</sup>Department of Medicine, Federal Teaching Hospital, Gombe, Nigeria.

<sup>3</sup>Department of Internal Medicine, LAUTECH Teaching Hospital, Ogbomosho, Oyo State, Nigeria.

<sup>4</sup>Department of Chemical Pathology, University of Ilorin, Kwara State, Nigeria.

### **Authors' contributions**

*This work was carried out in collaboration among all authors. Authors YAA and HIO designed the study. Author YAA performed the project work, analyzed, interpreted the data and wrote the first draft of the manuscript. Authors SAB, OMA, YAA, OGO and OMA designed, analyzed and interpreted the data, also contributor in writing the manuscript. All authors read and approved the final manuscript.*

### **Article Information**

DOI: 10.9734/JAMPS/2020/v22i430168

#### Editor(s):

(1) Dr. Palmiro Poltronieri, National Research Council of Italy, Rome.

#### Reviewers:

(1) Hoda Ali Mohamed Ibrahim, Tanta University, Egypt.

(2) Silviana Tirtasari, Tarumanagara University, Indonesia.

Complete Peer review History: <http://www.sdiarticle4.com/review-history/57561>

**Received 24 March 2020**

**Accepted 30 May 2020**

**Published 09 June 2020**

**Original Research Article**

### **ABSTRACT**

**Aims:** The study was aimed at determining the relationship between plasma homocysteine level and indices of severity in heart failure patients seen at a referral teaching hospital in Gombe, Northeast Nigeria.

**Study Design:** It was a hospital based cross-sectional study conducted on newly diagnosed heart failure patients managed by the cardiology unit of the Federal Teaching Hospital, Gombe, between May 2015 and December 2015.

**Methodology:** Ninety newly diagnosed Heart Failure patients who presented to the hospital along with 90 age and sex matched controls were recruited. All the subjects had clinical and Echocardiography evaluations. Homocysteine was assayed using enzyme-linked Immunosorbent Assay (ELISA) Kit for homocysteine designed by Cloud-clone Corp. Data was analyzed using the Statistical Package for Social Sciences for Windows (SPSS), Version 20.

**Results:** The mean left ventricular ejection fraction (LVEF) of the patients was  $35.4 \pm 9.81\%$  while that of the control group was  $62.1 \pm 7.04\%$  ( $P < 0.001$ ). The mean HCY of patients ( $11.61 \pm 8.00$   $\mu\text{mol/l}$ ) was higher than that of controls ( $10.24 \pm 6.98$   $\mu\text{mol/l}$ ), though not significantly;  $P=0.225$ . The 90th percentile of the homocysteine (HCY) levels in control was 20.9  $\mu\text{mol/l}$ . There was no significant relationship between plasma HCY level and the NYHA class of the patients, though post hoc analysis shows HCY level significantly increased from class I to other classes ( $P=0.034$ ,  $P=0.020$  and  $P=0.047$  respectively). The bivariate correlation between plasma HCY and Echocardiographic LV indices revealed no statistically significant relationship especially with the LVEF ( $r=0.149$ ,  $p=0.160$ ). However, the plasma HCY of the heart failure patients increased with increasing left ventricular mass index (LVMI) ( $r=0.246$ ,  $p=0.019$ ).

**Conclusion:** The study found that homocysteine levels are not significantly elevated in heart failure patients compared with healthy matched controls. However, elevated values were found with increasing left ventricular mass index. This might suggest a possible role of homocysteine in cardiac remodeling.

*Keywords: Heart failure; homocysteine; hyperhomocysteinaemia; Left Ventricular Mass Index (LVMI); North-Eastern Nigeria.*

## 1. INTRODUCTION

Heart Failure (HF) is a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood [1]. Heart failure is a progressive syndrome with high morbidity and mortality despite significant advancement in its treatment [2]. It is also a major public health problem world-wide that imposes a huge burden on the health care system [3].

About 20% of adults above 40 years of age have a lifetime risk of developing HF [2,4]. Worldwide, over 23 million individuals have HF and the prevalence continues to rise. Approximately 5.8 million persons in the United States have clinically manifest HF [5,6]. Although large scale studies on the prevalence of HF are scarce in Africa, including Nigeria, several studies have revealed a hospital admission rate of 3–7% for HF in general medical wards and over 30% in specialized cardiovascular units across the continent [7-9]. Unachukwu et al, found heart failure to be the third commonest noncommunicable cause of admission in a teaching hospital in Port Harcourt, Nigeria [10].

Hypertension, smoking, ischemic heart disease, rheumatic heart disease, diabetes mellitus, obesity, advancing age, among others, have been identified as the most important risk factors that predict the incidence of HF as well as its severity [9,11-15]. Therefore, identification of risk factors and risk indicators could help to prevent heart failure and ease the global burden of the disease. In the last decade, Plasma

Homocysteine (HCY) has emerged as a major vascular disease risk factor [16-17].

Hyperhomocysteinaemia (HHCY) is also commonly known as an independent risk factor for various cardiovascular diseases like endothelial dysfunction, vascular inflammation, atherosclerosis, hypertension, cardiac hypertrophy, neuro-degenerative and pregnancy associated disorders [18,19].

An increased incidence of HF was observed in individuals with elevated homocysteine (HCY) levels without prior Myocardial infarction (MI), suggesting a direct relationship between HHCY and HF [20]. Some of the mechanisms adduced for this relationship include; 1) increased cardiac fibrosis and increased activation of matrix metallo-proteinases, which in turn promote left ventricular remodeling and then HF; 2) activated matrix metallo-proteinases also causes endothelial and structural vascular dysfunction; 3) Hyperhomocysteinaemia induced direct negative inotropic and coronary vasodilatory effect; 4) Increased oxidative stress which is known to promote myocardial dysfunction [21, 22].

However, there is paucity of information on the relationship between plasma homocysteine levels and HF in Nigeria, especially in North-eastern Nigeria. Hence this study sets out to fill this gap by determining whether plasma total homocysteine levels are related to heart failure from all causes, and to severity of HF as measured by clinical and echocardiographic indices.

## 2. MATERIALS AND METHODS

The study was a hospital based cross-sectional analytical study conducted on newly diagnosed heart failure patients managed at the cardiology unit of the Federal Teaching Hospital, Gombe in North eastern Nigeria. The hospital is a tertiary health centre serving communities from all the states North East part of Nigeria. The study subjects included ninety newly diagnosed heart failure patients who presented to the Accident & Emergency Department and/or Cardiology Clinic of the hospital. Heart failure was defined using the Framingham Criteria [23].

Age and sex-matched controls that fulfilled the inclusion criteria were also included in the study. The controls were selected mainly from willing patients' relatives who shared the same diet and environmental conditions with the patients. Patients receiving Vitamin B derivatives, folic acid, anticonvulsants, Theophylline and Methotrexate were excluded from the study.

An informed written consent was obtained from the participants using a consent form which stated in clear and simple terms the purpose and importance of the study including the likely involved procedures.

Demographic and relevant clinical information were obtained from the patients and controls. A thorough physical examination with emphasis on the cardiovascular system was performed. Clinical diagnosis of HF was based on the Framingham's criteria of the concurrent presence of two major or one major with two minor criteria. Conventional trans-thoracic echocardiography (TTE) was used to evaluate subjects. Two-dimensional guided M-mode measurements were made according to the recommendations of the American Society of Echocardiography (ASE) convention [24-25]. Measurements were obtained in up to three cardiac cycles, according to the ASE convention and the average recorded.

Total plasma HCY was determined on overnight fasting samples drawn after about 8-10hrs of fasting. All blood samples were centrifuged within 1 hour of collection. About 2mls of plasma was collected using micropipette, transferred into new plain sample bottles and frozen at minus 20°C. Homocysteine was assayed using enzyme-linked Immunosorbent Assay (ELISA) Kit for homocysteine designed by Cloud-clone Corp. Abnormal total plasma HCY was defined as any

level above the 90th percentile in the distribution of HCY in the control population.

Data was analyzed using the Statistical Package for Social Sciences for Windows (SPSS), version 20. Demographic variables like age, sex and marital status were summarized using the mean for continuous variables, and proportions for categorical variables. Homocysteine levels in the subjects and control group were presented as mean and standard deviations. Mean homocysteine level was compared between subjects and control using independent sample t test. Patients were divided into four severity groups according to New York Heart Association (NYHA) classification and mean homocysteine was compared across the groups using analysis of variance (ANOVA). The relationship between left ventricular mass index (as an index of severity) and homocysteine was examined using Pearson's correlation. All the analyses were Two-Tailed, with statistical significance put at probability value of  $\leq 0.05$ .

## 3. RESULTS

A total of 180 subjects (90 patients and 90 age and sex matched controls) were recruited into this study and all of them were included in the analysis. The mean age of the patients was  $44.4 \pm 18.6$  years and was not significantly different from the mean age of the controls ( $P=0.467$ ) Table 1. The patient group comprised 31 males (34.4%) and 59 females (65.6%) while the control group consisted of 34 males (37.8%) and 56 females (62.2%); ( $P=0.642$ ). The mean weight of the patients ( $62.30 \pm 10.8$  kg) was significantly lower than that of the controls ( $66.8 \pm 13.4$  kg;  $P=0.013$ ) though no significant difference was observed in the height (Table 1)

The mean LVEF of the patients was  $35.4 \pm 9.81\%$  while that of the control group was  $62.1 \pm 7.04\%$  ( $P < 0.001$ ). This is shown in Table 2. Most of the patients presented with ejection fraction between 30% and 39%. Fig. 1

The mean HCY in patients with heart failure ( $11.61 \pm 8.00 \mu\text{mol/l}$ ) was higher than that of the controls ( $10.24 \pm 6.98 \mu\text{mol/l}$ ), though not significantly ( $P=0.225$ ) (Table 1). The 90th percentile of the HCY levels in the control was  $20.9 \mu\text{mol/l}$ . There was no significant difference in HCY in patients and control.

No significant relationship was observed between plasma HCY level and the NYHA class

of the patients though post hoc analysis showed HCY level significantly increased from class I to other classes (P=0.034, P=0.020 and P=0.047 respectively) (Table 3).

The bivariate correlation between plasma HCY and Echo LV indices revealed a statistically significant positive correlation between plasma HCY and PWTD (r= 0.255, P=0.015), IVSTD (r= 0.295, P=0.005) and LVMI (r =0.246, P=0.019).Table 4. Further comparison between HHCY and LVEF group showed no significant relationship. However, all those with LVEF greater than 40 had plasma HCY levels below

21umol/L which was used as the cut off (Table 5).


#### 4. DISCUSSION

Plasma homocysteine (HCY) has been suggested has an elevated marker in predicting the occurrence and severity of heart failure irrespective of the aetiology [26]. This index study showed a slightly higher but statistically insignificant mean HCY level among heart failure patients when compared to the healthy matched controls. The mean plasma HCY level is similar to what was reported by Okubadejo et al. [27] in stroke patients and by Ebesunun et al. [28]

**Table 1. Socio-demographic characteristics and clinical findings between patients and controls**

Variables	Patients n = 90 (%)	Control n = 90 (%)	t/ $\chi^2$	p value
Age (yrs.) Mean $\pm$ SD	44.42 $\pm$ 18.59	46.26 $\pm$ 14.92	0.730	0.467
Male	31 (34.4)	34 (37.8)	0.217	0.642
Female	59 (65.6)	56 (62.2)		
BMI Mean $\pm$ SD	22.80 $\pm$ 3.83	24.43 $\pm$ 5.29	-2.365	0.019*
Height (cm) Mean $\pm$ SD	165.3 $\pm$ 7.3	165.8 $\pm$ 8.1	0.398	0.691
Weight (kg) Mean $\pm$ SD	62.3 $\pm$ 10.8	66.3 $\pm$ 13.4	2.513	0.013*
Plasma HCY Mean $\pm$ SD	11.61 $\pm$ 8.00	10.24 $\pm$ 6.98	1.218	0.225

Key: t: Independent sample t-test;  $\chi^2$ : Chi square; \*: Statistically significant (i.e. P value < 0.05): SD=Standard deviation, BMI= body mass index



**Fig. 1. Pie chart showing classification of patients based on ejection fraction**

**Table 2. Comparison of echocardiographic findings between patients and controls**

Variables	Subject (n=90)	Control (n=90)	t	p value
LVIDD(cm)	5.99 ± 0.99	4.54 ± 0.44	12.670	< 0.001*
PWTD(cm)	0.99 ± 0.30	0.87 ± 0.14	3.409	0.001*
IVSTD(cm)	1.05 ± 0.29	0.90 ± 0.14	4.268	< 0.001*
LVIDS(cm)	4.90 ± 1.00	3.00 ± 0.45	16.377	< 0.001*
LVEF (%)	35.41 ± 9.82	62.06 ± 7.04	-20.924	< 0.001*
LVM(g)	257.34 ± 95.08	134.08 ± 33.01	11.618	< 0.001*
LVMI (g/m <sup>2</sup> )	184.80 ± 74.46	88.89 ± 21.93	11.721	< 0.001*
ARD(mm)	22.84 ± 11.08	27.78 ± 3.61	-4.018	< 0.001*
LAD(mm)	34.34 ± 17.67	29.40 ± 4.49	2.571	0.011*
E/A ratio	1.69 ± 0.79	1.47 ± 0.31	2.477	0.014*

Key: t: Independent sample t-test; \*: Statistically significant (i.e. p value < 0.05). LVIDd = left ventricular internal dimension in diastole, LVIDs = left ventricular internal dimension in systole, IVSTd=interventricular septal thickness in diastole, EF = Ejection fraction, LVM = left ventricular mass, LVMI = left ventricular mass index, LVEF= left ventricular ejection fraction, E/A = ratio of early ventricular inflow velocity to late ventricular inflow velocity, LAD= Left Atrial Enlargement SD=Standard deviation, CM=Centimeter, gm. = Gram

**Table 3. Comparison of plasma homocysteine levels with severity of heart failure (NYHA)**

Variables	NYHA				F	P value
	Class I n=3	Class II n=10	Class III n=32	Class IV n=45		
Plasma Homocysteine Mean ± SD	9.30 ± 1.91	12.76 ± 6.42	12.08 ± 8.63	11.08 ± 7.74	0.495	0.687

Post Hoc Tests showing the mean difference between classes

Variables	NYHA	Within NYHA	Mean Difference	p value
Plasma Homocysteine	Class I	Class II	-11.123	0.034*
		Class III	-11.296	0.020*
		Class IV	-9.444	0.047*
	Class II	Class I	11.123	0.034*
		Class III	-0.174	0.952
		Class IV	1.678	0.543
	Class III	Class I	11.296	0.020*
		Class II	-0.174	0.952
		Class IV	1.852	0.311
	Class IV	Class I	9.444	0.047*
		Class II	-1.678	0.543
		Class III	-1.852	0.311

F: One Way Anova; \*: Statistically significant (i.e. p value < 0.05), NYHA=New York Heart Association

amongst patients with Diabetes (10.2 ± 4.6 μmol/L and 10.5 ± 3.9 μmol/L respectively). Also, no significant difference was found by Okubadejo et al when compared with matched control. Glew et al in an earlier study of stroke and MI patients in Gombe has also shown no significant difference between patients and controls [29]. This is however in contrast to what was reported by Herrmann et al. when he compared 95 patients with systolic chronic HF

and 12 healthy persons without cardiac diseases. He reported a mean HCY of 17.1 μmol/L (± 20) and 9.6 μmol/L (± 2.6) in HF patients and control respectively (P < 0.01) [30]. This difference could be due to the fact that their controls, though small in number, were not matched for age and sex. Moreso, non fasting HCY was used in the study and this could have inadvertently elevated the mean HCY [31].

**Table 4. Correlation between plasma homocysteine levels and echocardiographic findings in patients with heart failure**

Variable	r	p value
Plasma Homocysteine		
LVIDD(cm)	-0.005	0.962
PWTD(cm)	-0.255	0.015*
IVSTD(cm)	-0.297	0.005*
LVIDS(cm)	0.069	0.517
LVEF (%)	-0.149	0.160
LVM(gm.)	0.295	0.005*
LVMI (g/m <sup>2</sup> )	0.246	0.019*
ARD(mm)	0.474	< 0.001*
LAD(mm)	0.456	< 0.001*
E/A ratio	0.024	0.825

Key: r: Pearson correlation coefficient; \*: Statistically significant (i.e. p value < 0.05), LVIDD= left ventricular internal dimension in diastole, PWTD= Posterior wall thickness in diastole, IVSTD= Interventricular septal thickness in diastole, LVEF = Ejection fraction, LVMI = left ventricular mass index, LVM= left ventricular mass, E/A ratio = ratio of early to late ventricular inflow velocity

**Table 5. Homocysteine and ejection fraction in subjects**

Variables	Homocysteine group		$\chi^2$	p value
	< 21 (n=83 (%))	≥ 21 (n=7 (%))		
Ejection Fraction				
< 30	26 (31.4)	2 (28.6)	4.359	0.225
30 – 39	30 (36.1)	5 (71.4)		
40 – 49	20 (24.1)	0 (0.0)		
≥ 50	7 (8.4)	0 (0.0)		

$\chi^2$ : Chi square

Hyperhomocysteinaemia (HHCY), HCY level greater than 90th percentile of control was present in 7.8% of the patients and 5.6% of the control (P=0.55). A similar non significant HHCY level was also reported by Okubadejo et al, among stroke patients and control, though with a lower cut off (HCY level >14.6umol/L) [27]. The relatively higher cut off for HHCY is perhaps reflecting very low intake of folate and vitamin B12 among northern Nigerians, an observation made in an earlier study [32]. Glew et al, has also suggested that the relatively high level of HCY in the people of Gombe region in northern Nigeria may be as a result of a high prevalence among the population of a mutation in the gene encoding 5,10-methylene tetrahydrofolate reductase (MTHFR) [29]. Mutations affecting the activity or expression of MTHFR have been shown to be associated with hyperhomocysteinaemia [33]. Several laboratories have varying cut off for HHCY that ranged from 15 to 20 umol/L especially in adults who do not supplement vitamins or eat folate fortified food [34]. Hence, the 90<sup>th</sup> percentile cut off value used in this index study still falls within the range quoted for the caucasian populations.

Plasma HCY has been found to have a linear relationship with severity of HF based on the NYHA classification in some earlier studies done among caucasians [22,30]. This study, after post hoc analysis, only revealed a significant increase between HCY level in those that presented in NYHA class 1 when compared with other classes. This observed non linear relationship may be explained by the fact that most of the patients would have sought alternative care from non orthodox practitioners, with several medications used, before presenting at the specialist center. This could have affected their plasma level of HCY unlike class 1 individuals who most likely presented earlier. Moreso, Glew et al, from his findings reported no significant rise in HCY level in patients with coronary artery disease risks within a similar population [29]. This finding is however in contrast to what was reported by Herrmann et al. [30] amongst HF patients in Germany. They reported a stepwise increase in mean total plasma HCY levels with increasing NYHA class, from 10.6umol/L in class I to 17.4 umol/L in class IV (p=0.002). The difference could be as a result of late presentation and also the relatively younger age

of our HF patients. Hence, plasma HCY levels do not directly correlate with the clinical severity of HF in the study population.

This study revealed no significant relationship between increasing HCY level and the LVEF in the subjects ( $P = 0.160$ ). However there is a correlation between the LVMI and mean HCY level ( $P = 0.019$ ). Data from the Framingham Study also revealed significant associations of HCY with left ventricular mass and left ventricular wall thickness. The Framingham's data also showed no relation between HCY and the echocardiographically assessed left ventricular function [35]. This was also reported by Wocial et al in subjects with essential hypertension [36]. This is however in contrast to what was reported by Vasan et al. [20] and Hermann et al. [30] where HCY level was found to have inversely correlated with LVEF. More so, clinical data relating plasma homocysteine to LV function have yielded inconsistent results. Negative, positive, and no association of plasma homocysteine with LV ejection fraction have been reported in referral samples of patients with coronary artery disease. [37] Several mechanisms have been adduced for the observed relationship between LVMI and plasma HCY levels which include; the critical role of homocysteine as a source of increased oxidative stress, a factor known to promote myocardial dysfunction. HHCY induced cardiac fibrosis and increased activation of matrix metalloproteinases, which in turn promote left ventricular remodeling, a known precursor of elevated LVMI [22]. Homocysteine also has growth-promoting and collagen production-stimulating effects on vascular smooth muscle cells and inhibitory effects on endothelial cell growth.

## 5. CONCLUSION

The study found that homocysteine levels are not significantly elevated in Nigerians with heart failure when compared to the healthy general population. The hyperhomocysteinaemia cut off in the study population is higher than the Caucasian reference value. Plasma HCY levels do not increase with heart failure severity (Using LVEF and NYHA). However, Plasma HCY levels increase with increasing left ventricular mass index (LVMI) which suggests its role in cardiac remodeling.

## CONSENT

Informed consent was obtained from all participants in the study.

## ETHICAL APPROVAL

The design of the study was approved by the Research and Ethics Committee of the Federal Teaching Hospital, Gombe.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*.
2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure the Framingham heart study. *Circulation*. 2002;106(24):3068-72.
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update. *Circulation*. 2014;129(3).
4. Djoussé L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. *Jama*. 2009;302(4):394-400.
5. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart*. 2007;93(9):1137-46.
6. Roger VL. Epidemiology of heart failure. *Circ Res*. 2013;113(6):646-59.
7. Damasceno A, Cotter G, Dzudie A, Sliwa K, Mayosi BM. Heart failure in sub-Saharan Africa: time for action. *J Am Coll Cardiol*. 2007;50(17):1688-93.
8. Kengne AP, Dzudie A, Sobngwi E. Heart failure in sub-Saharan Africa: A literature review with emphasis on individuals with diabetes. *Vasc Health Risk Manag*. 2008; 4(1):123.
9. Karaye KM, Sani MU. Factors associated with poor prognosis among patients admitted with heart failure in a Nigerian tertiary medical centre: A cross-sectional study. *BMC Cardiovasc Disord*. 2008;8 (1):1.
10. Unachukwu C, Agomuoh D, Alasia D. Pattern of non-communicable diseases among medical admissions in Port Harcourt, Nigeria. *Niger J Clin Pract*. 2008; 11(1):14-7.

11. Abengowe C. Cardiovascular disease in Northern Nigeria. *Trop Geogr Med.* 1979; 31(4):553-60.
12. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. *Nat Rev Cardiol.* 2011;8(1):30-41.
13. Amoah A, Kallen C. Aetiology of heart failure as seen from a National Cardiac Referral Centre in Africa. *Cardiology.* 2000; 93(1-2):11-8.
14. Ladipo G, Froude J, Parry E. Pattern of heart disease in adults of the Nigerian Savanna: A prospective clinical study. *Afr J Med Sci.* 1977;6(4):185-92.
15. Kingue S, Dzudie A, Menanga A, Akono M, Ouankou M, Muna W. [A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: Experience of the medicine department at Yaounde General Hospital]. *Ann Cardiol Angeiol (Paris).* 2005;54(5):276-83.
16. Refsum M, H, Ueland M, PM, Nygård M, O, Vollset M, Dr. PH, SE. Homocysteine and cardiovascular disease. *Annu Rev Med.* 1998;49(1):31-62.
17. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst (e) ine and cardiovascular disease: a critical review of the epidemiologic evidence. *Ann Intern Med.* 1999;131(5):363-75.
18. Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: An overview. *Clin Chem Lab Med.* 2001;39(8):666-74.
19. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. *Lancet.* 1999; 354(9176):407-13.
20. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. *Jama.* 2003;289(10):1251-7.
21. Vizzardi E, Bonadei I, Zanini G, Frattini S, Claudia C, Raddino R, et al. Homocysteine and heart failure: An overview. *Recent Pat Cardiovasc Drug Discov.* 2009;4(1):15-21.
22. Herrmann M, Taban-Shomal O, Hübner U, Böhm M, Herrmann W. A review of homocysteine and heart failure. *European Journal of Heart Failure.* 2006;8(6):571-6.
23. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. *N Engl J Med.* 1971;285(26):1441-6.
24. Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al. ACCF/AHA/ASA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. *J Am Coll Cardio.* 2011; 57(9):1126-66.
25. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015; 28(1):1-39. e14.
26. Naruszewicz M, Jankowska EA, Zymliński R, Bukowska H, Millo B, Banasiak W, et al. Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance pilot study. *Atherosclerosis.* 2007;194 (2):408-14
27. Okubadejo NU, Oladipo OO, Adeyomoye AA, Awosanya GO, Danesi MA. Exploratory study of plasma total homocysteine and its relationship to short-term outcome in acute ischaemic stroke in Nigerians. *BMC Neurol.* 2008;8(1):1
28. Ebesunun MO, Obajobi EO. Elevated plasma homocysteine in type 2 diabetes mellitus: A risk factor for cardiovascular diseases. *Pan Afr Med J.* 2012;12(1).
29. Glew RH, Okolie H, Crossey M, Suberu O, Trujillo M, Pereyra M, et al. Serum lipid profiles and homocysteine levels in adults with stroke or myocardial infarction in the town of Gombe in northern Nigeria. *J Health Popul Nutr.* 2004:341-7.
30. Herrmann M, Kindermann I, Müller S, Georg T, Kindermann M, Böhm M, et al. Relationship of plasma homocysteine with the severity of chronic heart failure. *Clin Chem.* 2005;51(8):1512-5
31. Fokkema MR, Gilissen MF, Van Doormaal JJ, Volmer M, Kema IP, Muskiet FA. Fasting vs nonfasting plasma



- homocysteine concentrations for diagnosis of hyperhomocysteinemia. Clin Chem. 2003;49(5):818-21.
32. Glew RH, Williams M, Conn CA, Cadena SM, Crossey M, Okolo SN, et al. Cardiovascular disease risk factors and diet of Fulani pastoralists of Northern Nigeria. Am J Clin Nutr. 2001; 74(6):730-6.
33. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-3.
34. Refsum H, Smith AD, Ueland PM, Nexø E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50(1):3-32
35. Sundström J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, et al. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. European Heart Journal. 2004;25(6):523-30.
36. Wocial B BH, Kostrubiec M, Kuczynska K, Kuch-Wocial A, N N. Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Press. 2002;11:201–5.
37. Sundström J, Vasan RS. Homocysteine and heart failure: A review of investigations from the Framingham Heart Study. Clin Chem Lab Med. 2005;43(10):987-92.

© 2020 Ayoola et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:  
<http://www.sdiarticle4.com/review-history/57561>*